Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant.

摘要: PURPOSEBone marrow transplant (BMT) can cure recurrent Hodgkin's disease, but more than half of patients will progress and require additional treatment. When this occurs, there are no curative options palliative therapy is usually indicated. In such patients, we have routinely used long-term vinblastine because its relatively low toxicity high activity.PATIENTS AND METHODSWe retrospectively reviewed the charts all with disease who relapsed after autologous BMT since 1991. Of 23 16 received vinblastine; also include our index case, began following relapse in 1987. Patients 4 to 6 mg/m2 every 1 2 weeks, continued until evidence progression.RESULTSThe 17 report had a median age 31 years, performance status 2, three prior regimens, 12 (71%) were advanced stage. Ten (59%) objective responses, which two (12%) complete (CR) ...